Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Immunovant (IMVT) Leases (2020 - 2026)

Immunovant filings provide 6 years of Leases readings, the most recent being $98000.0 for Q1 2025.

  • Quarterly Leases fell 26.32% to $98000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $98000.0 through Mar 2025, down 26.32% year-over-year, with the annual reading at $98000.0 for FY2025, 26.32% down from the prior year.
  • Leases hit $98000.0 in Q1 2025 for Immunovant, up from $22000.0 in the prior quarter.
  • Across five years, Leases topped out at $3.3 million in Q1 2021 and bottomed at $22000.0 in Q4 2024.
  • Average Leases over 5 years is $1.3 million, with a median of $1.2 million recorded in 2023.
  • The largest annual shift saw Leases decreased 21.82% in 2021 before it crashed 92.52% in 2024.
  • Immunovant's Leases stood at $2.5 million in 2021, then plummeted by 40.5% to $1.5 million in 2022, then plummeted by 79.85% to $294000.0 in 2023, then crashed by 92.52% to $22000.0 in 2024, then skyrocketed by 345.45% to $98000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Leases are $98000.0 (Q1 2025), $22000.0 (Q4 2024), and $45000.0 (Q3 2024).